{"entity":{"id":"nct07060365","kind":"trial","name":"A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is withdrawn.","summary":"The registry lists NCT07060365 as withdrawn, last updated 2026-04-03. Enrolment is 0 actual participants. Interventions: Saruparib. Primary measures include Number of participants with treatment-emergent adverse event (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation. The registry reason for stopping is: The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns. No results are posted in the registry; this does not exclude separate publications.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07060365","url":"https://clinicaltrials.gov/study/NCT07060365"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07060365","phase":"1/2","setting":"A Master Protocol Phase I/II Study to Investigate Biomarker-Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants With Advanced/Recurrent Ovarian Cancer (Ovarian Platform)","sponsor":"AstraZeneca","started":"2025-09-02","startedType":"actual","enrolled":0,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07060365/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}